vs
Side-by-side financial comparison of ARDELYX, INC. (ARDX) and CAMDEN NATIONAL CORP (CAC). Click either name above to swap in a different company.
ARDELYX, INC. is the larger business by last-quarter revenue ($94.5M vs $64.3M, roughly 1.5× CAMDEN NATIONAL CORP). CAMDEN NATIONAL CORP runs the higher net margin — 34.0% vs -39.8%, a 73.8% gap on every dollar of revenue. Over the past eight quarters, CAMDEN NATIONAL CORP's revenue compounded faster (22.6% CAGR vs 13.6%).
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.
ARDX vs CAC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $94.5M | $64.3M |
| Net Profit | $-37.6M | $21.9M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -39.8% | 34.0% |
| Revenue YoY | 27.5% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.15 | $1.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $94.5M | $64.3M | ||
| Q4 25 | $125.2M | $68.1M | ||
| Q3 25 | $110.3M | $65.4M | ||
| Q2 25 | $97.7M | $62.3M | ||
| Q1 25 | $74.1M | $60.1M | ||
| Q4 24 | $116.1M | $47.6M | ||
| Q3 24 | $98.2M | $45.0M | ||
| Q2 24 | $73.2M | $42.8M |
| Q1 26 | $-37.6M | $21.9M | ||
| Q4 25 | $-407.0K | $22.6M | ||
| Q3 25 | $-969.0K | $21.2M | ||
| Q2 25 | $-19.1M | $14.1M | ||
| Q1 25 | $-41.1M | $7.3M | ||
| Q4 24 | $4.6M | $14.7M | ||
| Q3 24 | $-809.0K | $13.1M | ||
| Q2 24 | $-16.5M | $12.0M |
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | — | ||
| Q3 25 | 96.4% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | 84.3% | — | ||
| Q3 24 | 84.0% | — | ||
| Q2 24 | 87.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 41.5% | ||
| Q3 25 | 4.2% | 40.5% | ||
| Q2 25 | -14.7% | 28.5% | ||
| Q1 25 | -49.0% | 10.3% | ||
| Q4 24 | 7.0% | 38.7% | ||
| Q3 24 | 2.3% | 35.2% | ||
| Q2 24 | -18.6% | 34.7% |
| Q1 26 | -39.8% | 34.0% | ||
| Q4 25 | -0.3% | 33.1% | ||
| Q3 25 | -0.9% | 32.4% | ||
| Q2 25 | -19.5% | 22.6% | ||
| Q1 25 | -55.5% | 12.2% | ||
| Q4 24 | 4.0% | 30.8% | ||
| Q3 24 | -0.8% | 29.1% | ||
| Q2 24 | -22.5% | 28.0% |
| Q1 26 | $-0.15 | $1.29 | ||
| Q4 25 | $-0.01 | $1.33 | ||
| Q3 25 | $0.00 | $1.25 | ||
| Q2 25 | $-0.08 | $0.83 | ||
| Q1 25 | $-0.17 | $0.43 | ||
| Q4 24 | $0.01 | $1.00 | ||
| Q3 24 | $0.00 | $0.90 | ||
| Q2 24 | $-0.07 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.1M | — |
| Total DebtLower is stronger | $203.5M | $514.4M |
| Stockholders' EquityBook value | $148.6M | $710.0M |
| Total Assets | $504.5M | $7.0B |
| Debt / EquityLower = less leverage | 1.37× | 0.72× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $238.1M | — | ||
| Q4 25 | $68.0M | — | ||
| Q3 25 | $42.7M | — | ||
| Q2 25 | $90.0M | — | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $64.9M | — | ||
| Q3 24 | $47.4M | — | ||
| Q2 24 | $41.9M | — |
| Q1 26 | $203.5M | $514.4M | ||
| Q4 25 | $202.8M | — | ||
| Q3 25 | $202.1M | — | ||
| Q2 25 | $201.4M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | $150.9M | — | ||
| Q3 24 | $100.7M | — | ||
| Q2 24 | $100.2M | — |
| Q1 26 | $148.6M | $710.0M | ||
| Q4 25 | $166.9M | $696.6M | ||
| Q3 25 | $154.3M | $676.4M | ||
| Q2 25 | $139.5M | $652.1M | ||
| Q1 25 | $145.7M | $640.1M | ||
| Q4 24 | $173.3M | $531.2M | ||
| Q3 24 | $158.3M | $529.9M | ||
| Q2 24 | $147.0M | $508.3M |
| Q1 26 | $504.5M | $7.0B | ||
| Q4 25 | $501.6M | $7.0B | ||
| Q3 25 | $486.2M | $7.0B | ||
| Q2 25 | $466.8M | $6.9B | ||
| Q1 25 | $410.2M | $7.0B | ||
| Q4 24 | $435.8M | $5.8B | ||
| Q3 24 | $367.9M | $5.7B | ||
| Q2 24 | $343.5M | $5.7B |
| Q1 26 | 1.37× | 0.72× | ||
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
